Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07776782
PHASE1
A Phase 1 Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants
Sponsor: Mirador Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants
Official title: A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered With Concomitant Infliximab in Healthy Participants
Key Details
Gender
All
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2026-07-16
Completion Date
2026-11-12
Last Updated
2026-08-20
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
MT-201
MT-201 and Infliximab
Locations (1)
Mirador Clinical Department
San Diego, California, United States